  |
Neonatal Drug Therapy Manual |
Intravenous Immune Globulin (IVIG)
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
Classification:
Blood Product Derivative; Immune Globulin
Indications:
- Isoimmune hemolytic disease (Rh-incompatibility)
- Immune thrombocytopenia (ITP)
Administration:
- Administer IV slowly and titrate as tolerated over 2 hours
- TOH: refer to protocol for administration
Dosage:
- Isoimmune hemolytic disease (Rh-incompatibility):
- 500 - 1000 mg/kg/dose IV once over 2 hours; if needed, dose may be repeated in 12 hours
- Most effective when administered as soon as possible after diagnosis
- Immune thrombocytopenia (ITP):
- 400 to 1000 mg/kg/day IV for 2 to 5 consecutive days (total dose: 2000 mg/kg)
- Maintenance dose: 400 to 1000 mg/kg/dose IV every 3 to 6 weeks based on clinical response and platelet count
Side Effects:
- CNS: fever
- CVS: tachycardia, hypotension
- Dermatologic: rash
Reconstitution and Stability:
- Obtain from Blood Bank
- Stability is dependent upon the manufacturer and brand
Compatibility:
- Solution Compatible: D5W, D5W-0.2% NaCl, D15W
References:
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc; 2015
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.
